Abstract: The disclosure is directed to systems and method with improved coordination for multiple parametric test channels. The system can be configured to receive a testing routine and distribute test operations to a plurality of test channels comprising channel processors, testing circuits coupled to test pins configurable to be connected to the device under test (DUT), and trigger interfaces coupled to the testing circuits. Additionally, some implementations can include a hub device coupled to the processing system and to the trigger interfaces, the hub device includes programmable logic gates configured to define a trigger group including at least two of the trigger interfaces and to generate trigger signals according to the testing routine. Further, at least a portion of the channel processors perform operations according to the testing routine upon receipt of the trigger signals. The disclosure enables synchronized yet autonomous multi-channel testing that improves test throughput and timing accuracy.

Abstract: The disclosure describes systems and methods for parametric multi-channel testing of semiconductor devices. A system provides multiple test channels that include a pulse resource and a measuring resource with high-current (HC) and low-current (LC) switches coupled to a potential node connected to a testing pin. The pulse resource includes a first branch with a pulse generator, programmable-gain amplifier, switches for different branches or operations providing pulse current/voltage monitoring and a high-speed switch. A mode switch can be incorporated to selectively connect the potential node to the pulse resource for pulse testing, to the measuring resource with the HC switch closed for high-potential testing, or to the measuring resource with the LC switch closed for low-potential testing.

Abstract: A transmitting device for generating a plurality of encoded portions of a video to be transmitted to a receiving device over a network configured to: receive an error message over a feedback channel from the receiving device indicating at least one of said plurality of encoded portions that has been lost at the receiving device; encode a recovery portion responsive to said receiving said error message; and transmit said recovery portion to the receiving device over said network; wherein said error message includes information pertaining to a decoded portion successfully decoded at the receiving device and said recovery portion is encoded relative to said decoded portion.

Abstract: A transmitting device for generating a plurality of encoded portions of a video to be transmitted to a receiving device over a network configured to: receive an error message over a feedback channel from the receiving device indicating at least one of said plurality of encoded portions that has been lost at the receiving device; encode a recovery portion responsive to said receiving said error message; and transmit said recovery portion to the receiving device over said network; wherein said error message includes information pertaining to a decoded portion successfully decoded at the receiving device and said recovery portion is encoded relative to said decoded portion.

Abstract: An assembly and method for producing a condensation aerosol are disclosed. The assembly includes a heat-conductive metal substrate with an oxidation resistant exterior surface and a drug composition film on the exterior surface and is for use in an aerosol device. The thickness of the film and the surface of the substrate is such that the aerosol formed by vaporizing and condensing the drug composition the aerosol contain 10% by weight or less drug-degradation products and at least 50% of the total amount of the drug composition in the film. The methods for treating the exterior surface include heat and chemical treatment and formation of a protective overcoat.

Abstract: A transmitting device for generating a plurality of encoded portions of a video to be transmitted to a receiving device over a network configured to: receive an error message over a feedback channel from the receiving device indicating at least one of said plurality of encoded portions that has been lost at the receiving device; encode a recovery portion responsive to said receiving said error message; and transmit said recovery portion to the receiving device over said network; wherein said error message includes information pertaining to a decoded portion successfully decoded at the receiving device and said recovery portion is encoded relative to said decoded portion.

Abstract: A transmitting device for generating a plurality of encoded portions of a video to be transmitted to a receiving device over a network configured to: receive an error message over a feedback channel from the receiving device indicating at least one of said plurality of encoded portions that has been lost at the receiving device; encode a recovery portion responsive to said receiving said error message; and transmit said recovery portion to the receiving device over said network; wherein said error message includes information pertaining to a decoded portion successfully decoded at the receiving device and said recovery portion is encoded relative to said decoded portion.

Abstract: An assembly and method for producing a condensation aerosol are disclosed. The assembly includes a heat-conductive metal substrate with an oxidation resistant exterior surface and a drug composition film on the exterior surface and is for use in an aerosol device. The thickness of the film and the surface of the substrate is such that the aerosol formed by vaporizing and condensing the drug composition the aerosol contain 10% by weight or less drug-degradation products and at least 50% of the total amount of the drug composition in the film. The methods for treating the exterior surface include heat and chemical treatment and formation of a protective overcoat.

Abstract: An assembly and method for producing a condensation aerosol are disclosed. The assembly includes a heat-conductive metal substrate with an oxidation resistant exterior surface and a drug composition film on the exterior surface and is for use in an aerosol device. The thickness of the film and the surface of the substrate is such that the aerosol formed by vaporizing and condensing the drug composition the aerosol contain 10% by weight or less drug-degradation products and at least 50% of the total amount of the drug composition in the film. The methods for treating the exterior surface include heat and chemical treatment and formation of a protective overcoat.

Abstract: A device, method, and system for producing a condensation aerosol are disclosed. The device includes a chamber having an upstream opening and a downstream opening which allow gas to flow through the chamber, and a heat-conductive substrate located at a position between the upstream and downstream openings. Formed on the substrate is a drug composition film containing a therapeutically effective dose of a drug when the drug is administered in aerosol form. A heat source in the device is operable to supply heat to the substrate to produce a substrate temperature greater than 300° C., and to substantially volatilize the drug composition film from the substrate in a period of 2 seconds or less. The device produces an aerosol containing less than about 10% by weight drug composition degradation products and at least 50% of the drug composition of said film.

Abstract: An article for use in an aerosol device, for producing an aerosol of a drug composition is disclosed. The article includes a heat-conductive substrate having a surface with a selected surface area, and a drug composition film on the substrate surface having a selected film thickness of between 0.05 and 20 ?m. The film thickness is such that an aerosol formed by vaporizing the drug composition by heating the substrate and condensing the vaporized compound contains 10% or less drug-degradation product and at least 50% of the total amount of drug composition contained in the film. The selected substrate surface area is such as to yield an effective human therapeutic dose of the drug aerosol. Also disclosed are methods of making and using the article.

Abstract: The present invention provides novel condensation aerosols for the treatment of disease and/or intermittent or acute conditions. These condensation aerosols have little or no pyrolysis degradation products and are characterized by having an MMAD of between 1-3 microns. These aerosols are made by rapidly heating a substrate coated with a thin film of drug having a thickness of between 0.05 and 20 ?m, while passing a gas over the film, to form particles of a desirable particle size for inhalation. Kits comprising a drug and a device for producing a condensation aerosol are also provided. The device contained in the kit typically, has an element for heating the drug which is coated as a film on the substrate and contains a therapeutically effective dose of a drug when the drug is administered in aerosol form, and an element allowing the vapor to cool to form an aerosol. Also disclosed, are methods for using these aerosols and kits.

Abstract: Described herein are diuretic condensation aerosols and methods of making and using them. Kits for delivering a condensation aerosol are also described. The diuretic aerosols typically comprise diuretic condensation aerosol particles that comprise a diuretic compound. In some variations the diuretic compound is selected from the group consisting of bumetanide, ethacrynic acid, furosemide, muzolimine, spironolactone, torsemide, triamterene, tripamide, BG 9928, and BG 9719. Methods of treating edema using the described aerosols are also provided. In general, the methods typically comprise the step of administering a therapeutically effective amount of diuretic condensation aerosol to a person with edema. The diuretic condensation aerosol may be administered in a single inhalation, or may be administered in more than one inhalation. Methods of forming a diuretic condensation aerosol are also described.

Abstract: The present invention provides novel condensation aerosols for the treatment of disease and/or intermittent or acute conditions. These condensation aerosols have little or no pyrolysis degradation products and are characterized by having an MMAD of between 1-3 microns. These aerosols are made by rapidly heating a substrate coated with a thin film of drug having a thickness of between 0.05 and 20 ?m, while passing a gas over the film, to form particles of a desirable particle size for inhalation. Kits comprising a drug and a device for producing a condensation aerosol are also provided The device contained in the kit typically, has an element for heating the drug which is coated as a film on the substrate and contains a therapeutically effective dose of a drug when the drug is administered in aerosol form, and an element allowing the vapor to cool to form an aerosol. Also disclosed, are methods for using these aerosols and kits.

Abstract: An article for use in an aerosol device, for producing an aerosol of a drug composition is disclosed. The article includes a heat-conductive substrate having a surface with a selected surface area, and a drug composition film on the substrate surface having a selected film thickness of between 0.05 and 20 ?m. The film thickness is such that an aerosol formed by vaporizing the drug composition by heating the substrate and condensing the vaporized compound contains 10% or less drug-degradation product and at least 50% of the total amount of drug composition contained in the film. The selected substrate surface area is such as to yield an effective human therapeutic dose of the drug aerosol. Also disclosed are methods of making and using the article.

Abstract: A device, method, and system for producing a condensation aerosol are disclosed. The device includes a chamber having an upstream opening and a downstream opening which allow gas to flow through the chamber, and a heat-conductive substrate located at a position between the upstream and downstream openings. Formed on the substrate is a drug composition film containing a therapeutically effective dose of a drug when the drug is administered in aerosol form. A heat source in the device is operable to supply heat to the substrate to produce a substrate temperature greater than 300° C., and to substantially volatilize the drug composition film from the substrate in a period of 2 seconds or less. The device produces an aerosol containing less than about 10% by weight drug composition degradation products and at least 50% of the drug composition of said film.

Abstract: Methods of treating headache with antipsychotics are provided. A kit for treating headache is also provided, comprising an antipsychotic and a device for rapid delivery of the antipsychotic.

Abstract: Methods for determining the film thickness of a compound composition needed to provide a selected purity and yield of a condensation aerosol via vaporization of the compound composition have applications in aerosol delivery technology, in pulmonary drug delivery, and in other therapeutic treatment regimes. The methods for determining such film thickness, for use in a device having a film of drug composition to be aerosolized, include generating purities and yields of a drug composition by vaporizing films of the drug composition from substrates at two or more temperatures in the range of 150° C. to 500° C. and two or more film thickness in the range of 0.05 to 50 microns, determining from these yields and purities if a thickness and temperature exist where the aerosol has at least 90% purity and at least 50% yield, and repeated such measurements until the selected purity and yield requirement are met.

Abstract: An assembly and method for producing a condensation aerosol are disclosed. The assembly includes a heat-conductive metal substrate with an oxidation resistant exterior surface and a drug composition film on the exterior surface and is for use in an aerosol device. The thickness of the film and the surface of the substrate is such that the aerosol formed by vaporizing and condensing the drug composition the aerosol contain 10% by weight or less drug-degradation products and at least 50% of the total amount of the drug composition in the film. The methods for treating the exterior surface include heat and chemical treatment and formation of a protective overcoat.